Predicting the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
This prognostic model can be used to predict and estimate the 1-year, 2-year, 3-year, and 5-year survival probability and median survival months of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma.
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Margit Mägi, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen
Details Files & References
Composite
Model author
Version
2.7
Revision date
2019-03-25
MeSH terms
No MeSH classifications added
Status
public
Share

Related files

No related files available

{{ resultSubheader }}

{{ model.survival.PITTitle }}

{{ model.survival.YNETitle }}

Results
Note
Notes are only visible in the result download and will not be saved by Evidencio

Composite model

Conditional information

Result interpretation

{{ file.classification }}

Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

Comments
Rating
Comment
Please enter a comment of rating
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
Underlying models
1-year survival of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Margit Mägi, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen
2-year survival of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Margit Mägi, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen
3-year survival of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Margit Mägi, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen
5-year survival of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Margit Mägi, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen
Median survival of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma
Research authors: Lei Huang, Yesilda Balavarca, Lydia van der Geest, Valery Lemmens, Liesbet Van Eycken, Harlinde De Schutter, Tom B. Johannesen, Vesna Zadnik, Maja Primic-Žakelj, Maja Primic-Žakelj, Robert Grützmann, Marc G.H. Besselink, Petra Schrotz-King, Hermann Brenner, Lina Jansen